Answers are grounded in this paper and cite their sources.
R-pyocins, bacteriocin-like proteins produced by Pseudomonas aeruginosa, present a promising alternative to phage therapy and/or adjunct to currently used antimicrobials in treating bacterial infections due to their targeted specificity, lack of replication, and stability. This review explores the structural, mechanistic, and therapeutic aspects of R-pyocins, including their potential for chronic infection management, and discusses recent advances in delivery methods, paving the way for novel antimicrobial applications in clinical settings.
No takes yet. Share an insight, caveat, or question.
Mei et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: